株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の皮膚科医薬品市場 2023年:乾癬およびアトピー性皮膚炎向けインターロイキン受容体阻害剤の普及拡大が促進する成長

Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis

発行 GBI Research 商品コード 540334
出版日 ページ情報 英文 136 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
世界の皮膚科医薬品市場 2023年:乾癬およびアトピー性皮膚炎向けインターロイキン受容体阻害剤の普及拡大が促進する成長 Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis
出版日: 2017年07月01日 ページ情報: 英文 136 Pages
概要

世界の皮膚科医薬品市場における収益は、2016年の198億米ドルから2023年に366億米ドルへ、9.13%のCAGR (年間複合成長率) で拡大すると予測されています。

当レポートでは、皮膚科医薬品市場について調査し、主な上市製品のプロファイルとその収益予測を含む皮膚科市販薬情勢の概要、皮膚科医薬品のパイプライン分析、世界・主要国における市場予測、および企業情勢の評価などを提供しています。

第1章 目次

第2章 イントロダクション

第3章 主な上市製品

  • 概要
  • Humira (adalimumab) - AbbVie
  • Remicade (infliximab) - Johnson & Johnson
  • Enbrel (etanercept) - Amgen
  • Stelara (ustekinumab) - Johnson & Johnson
  • Neoral (cyclosporine) - Novartis
  • Protopic (tacrolimus) - Astellas Pharma
  • Cosentyx (Secukinumab) - Novartis
  • Dupixent (dupilumab) Sanofi and Regeneron
  • Taltz (ixekizumab) - Eli Lilly
  • Eucrisa (crisaborole) - Pfizer
  • Siliq (Brodalumab) - Valeant Pharmaceuticals
  • Elidel (pimecrolimus)
  • Elocon (mometasone furoate)
  • Differin (adapalene)
  • Metolate (methotrexate)
  • Clobex (clobetasol propionate)
  • 結論

第4章 パイプライン情勢評価

  • 概要
  • パイプラインにおける分子タイプ
  • パイプラインにおける分子標的
  • 治験
  • 結論

第5章 マルチシナリオ市場予測

  • 全体的な市場規模
  • ジェネリック医薬品の浸透
  • 収益予測:分子標的別

第6章 企業分析・ポジショニング

  • 収益・市場シェア分析:企業別
  • 競合情勢
  • 上市・パイプラインポートフォリオ分析

第7章 戦略的結論

  • ライセンシング契約
  • 共同開発契約

第8章 付録

図表一覧

目次
Product Code: GBIHC447MR

Executive Summary:

Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 types of dermatological conditions are thought to exist, ranging from the autoimmune disorder psoriasis to the very common condition acne vulgaris. The scope of dermatological disorders is diverse in terms of severity and clinical presentation, and if a condition is not sufficiently kept under control, it can significantly impair the patient's quality of life. For example, patients with severe atopic dermatitis (the most common form of eczema) may experience mobility impairments and debilitating itching, which may interfere with daily activities. Furthermore, most dermatological conditions are visible, and as such can have a profound impact on patient confidence.

There are 850 products in the dermatology pipeline with a disclosed stage of development, but the majority of these drugs are at an early stage of development. Some 42% of the pipeline is in the Preclinical stage, while 14% is in the discovery stage. However, 32% of the pipeline is in clinical development, but only 3% are in the Pre-registration stage and less than half are novel.

Four drugs that were approved for psoriasis are Cosentyx, Otezla, Eucrisa and Taltz. The most notable of the four are Cosentyx and Otezla, which were approved in 2015 and 2014, respectively, and are forecast to generate $3.8 billion and $2.7 billion from the therapy area in 2023, respectively. The two most recently approved psoriasis treatments, Taltz and Eucrisa, are not expected to achieve the same level of commercial success as Cosentyx or Otezla because they are entering a market that is already saturated with entrenched competitors that have reduced the level of unmet need.

Dermatology therapy area is dominated by top 20 pharma companies. In 2016 the most commercially successful companies in the therapy area were Johnson & Johnson, AbbVie, Amgen, Novartis and Pfizer. Across the forecast period these companies will continue to generate high revenue, but the companies will all see their market shares change.

The report "Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis" provides an introduction to dermatology, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications. Disease classification and methods of diagnosis are also provided.

In depth, this report provides the following:

  • Provides an overview of the dermatology marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the dermatology pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: atopic dermatitis, acne vulgaris and psoriasis.
  • Presents forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided.
  • Assesses the company landscape in dermatology, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area composes a large proportion of each company's pipeline portfolio and total revenues.

Companies mentioned in this report: Johnson & Johnson, AbbVie, Amgen, Novartis, Pfizer

Scope:

  • Global revenue from the dermatology market is forecast to increase from $19.8 billion in 2016 to $36.6 billion in 2023, at a compound annual growth rate of 9.13%. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
  • What are the leading companies in terms of market share?
  • Which companies are forecast to experience the largest growth in market share?
  • Which companies rely heavily on revenue derived from antibacterial drugs?
  • How will the market respond to recent approvals?
  • Will generics and biosimilars have a significant impact on the market over the forecast period?
  • What class of drugs dominate the market?
  • What molecular targets are most popular in the pipeline?
  • What are the commercial prospects for the most promising late-stage products?

Reasons to buy:

  • Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug's mechanism of action.
  • Analyze the dermatology pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
  • This review also provides a detailed look at dermatology product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market.
  • Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
  • 2.2. Symptoms
  • 2.3. Etiology and Pathophysiology
    • 2.3.1. Atopic Dermatitis
    • 2.3.2. Acne Vulgaris
    • 2.3.3. Psoriasis
  • 2.4. Co-morbidities and Complications
  • 2.5. Diagnosis, Scales and Grading
    • 2.5.1. Atopic Dermatitis
    • 2.5.2. Acne Vulgaris
    • 2.5.3. Psoriasis
  • 2.6. Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation
    • 2.6.1. Atopic Dermatitis
    • 2.6.2. Acne Vulgaris
    • 2.6.3. Psoriasis
  • 2.7. Treatment
    • 2.7.1. Topical Corticosteroids
    • 2.7.2. Calcineurin Inhibitors
    • 2.7.3. Retinoids
    • 2.7.4. Systemic Immunosuppressive Agents
    • 2.7.5. Biologics
    • 2.7.6. Antihistamines
    • 2.7.7. Hormonal Therapy
    • 2.7.8. Moisturizers

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. Humira (adalimumab) - AbbVie
  • 3.3. Remicade (infliximab) - Johnson & Johnson
  • 3.4. Enbrel (etanercept) - Amgen
  • 3.5. Stelara (ustekinumab) - Johnson & Johnson
  • 3.6. Neoral (cyclosporine) - Novartis
  • 3.7. Protopic (tacrolimus) - Astellas Pharma
  • 3.8. Cosentyx (Secukinumab) - Novartis
  • 3.9. Dupixent (dupilumab) Sanofi and Regeneron
  • 3.10. Taltz (ixekizumab) - Eli Lilly
  • 3.11. Eucrisa (crisaborole) - Pfizer
  • 3.12. Siliq (Brodalumab) - Valeant Pharmaceuticals
  • 3.13. Elidel (pimecrolimus)
  • 3.14. Elocon (mometasone furoate)
  • 3.15. Differin (adapalene)
  • 3.16. Metolate (methotrexate)
  • 3.17. Clobex (clobetasol propionate)
  • 3.18. Conclusion

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Molecule Types in the Pipeline
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.2. Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.3. Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.4. Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.5. Assessment of Key Pipeline Products
  • 4.5. Conclusion

5. Multi-scenario Market Forecast to 2023

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
  • 5.3. Revenue Forecast by Molecular Target
    • 5.3.1. Tumor Necrosis Factor-Alpha
    • 5.3.2. Interleukins 1, 4, 5, 12, 17 and 23 and Receptors
    • 5.3.3. Calcineurin
    • 5.3.4. Glucocorticoid Receptors
    • 5.3.5. Phosphodiesterase 4

6. Company Analysis and Positioning

  • 6.1. Revenue and Market Share Analysis by Company
    • 6.1.1. Novartis - Will Revenue from Cosentyx Continue to Increase in the Forecast Period?
    • 6.1.2. AbbVie - Will Humira's Patent Expiry Lead to Loss of Market Leadership?
    • 6.1.3. Johnson & Johnson - Guselkumab and Stelara Fail to Offset Revenue Lost from Remicade
    • 6.1.4. Sanofi - High Revenue Growth from Dupixent Will See Sanofi's Revenue from the Dermatology Therapy Area Increase
    • 6.1.5. Pfizer - Approval of Eucrisa to Drive Growth in the Dermatology Therapy Area
    • 6.1.6. Celgene - Otezla Expected to Achieve Blockbuster Status in the Therapy Area
  • 6.2. Company Landscape
  • 6.3. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deals by Region, Year and Value
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.1.4. Figures for Licensing Deals Valued Above $100m
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Year and Value
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.2.4. Figures for Co-development Deals Valued Above $100m

8. Appendix

  • 8.1. References
  • 8.2. Table of Epidemiology Forecast
  • 8.3. Figure of All Clinical Stage Psoriasis ,Atopic dermatitis and Acne vulgaris Pipeline Products
  • 8.4. Abbreviations
  • 8.5. Disease List
  • 8.6. Methodology
    • 8.6.1. Coverage
    • 8.6.2. Secondary Research
    • 8.6.3. Market Size and Revenue Forecasts
    • 8.6.4. Pipeline Analysis
    • 8.6.5. Competitive Landscape
  • 8.7. Contact Us
  • 8.8. Disclaimer

List of Tables

  • Table 1: Dermatology, Global, Classification of Atopic Dermatitis Severity and Impact on Quality of Life
  • Table 2: Dermatology, Global, European Dermatology Forum Acne Vulgaris Classification
  • Table 3: Dermatology, Global, Classification of Acne Vulgaris Severity
  • Table 4: Dermatology, Global, Classification of Psoriasis Severity
  • Table 5: Dermatology, Global, Epidemiology of Dermatological Disorders, 2016
  • Table 6: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Humira, 2017
  • Table 7: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Remicade, 2017
  • Table 8: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Enbrel, 2017
  • Table 9: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Stelara, 2017
  • Table 10: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Neoral, 2017
  • Table 11: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Protopic, 2017
  • Table 12: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Cosentyx, 2017
  • Table 13: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Dupixent, 2017
  • Table 14: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Taltz, 2017
  • Table 15: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Eucrisa, 2017
  • Table 16: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Siliq, 2017
  • Table 17: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Elidel, 2015
  • Table 18: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Elocon, 2015
  • Table 19: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Differin, 2015
  • Table 20: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Metolate, 2017
  • Table 21: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Clobex, 2017
  • Table 22: Dermatology Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($bn), 2016-2023
  • Table 23: Dermatology, Global, Usage of Generics Across Key Indications, 2017
  • Table 24: Dermatology Therapeutics Market, Global, Forecast Revenue by Company, 2016-2023
  • Table 25: Epidemiology Patterns for Atopic Dermatitis, 2015-2022
  • Table 26: Epidemiology Patterns for Acne Vulgaris, 2015-2022
  • Table 27: Epidemiology Patterns for Psoriasis, 2015-2022
  • Table 28: Abbreviations

List of Figures

  • Figure 1: Epidemiology Patterns for Atopic Dermatitis (million), 2016-2023
  • Figure 2: Epidemiology Patterns for Acne Vulgaris (million), 2016-2023
  • Figure 3: Epidemiology Patterns for Psoriasis (million), 2016-2023
  • Figure 4: Dermatology, Global, Key Marketed Products and Approved Indications, 2017
  • Figure 5: Dermatology Therapeutics Market, Global, Annual Revenue for Humira ($bn), 2006-2023
  • Figure 6: Dermatology Therapeutics Market, Global, Johnson & Johnson's Annual Revenue for Remicade ($bn), 2006-2023
  • Figure 7: Dermatology Therapeutics Market, Global, Merck & Co.'s Annual Revenue for Remicade ($bn), 2010-2023
  • Figure 8: Dermatology Therapeutics Market, Global, Amgen's Annual Revenue for Enbrel ($bn), 2006-2023
  • Figure 9: Dermatology Therapeutics Market, Global, Pfizer's Annual Revenue for Enbrel ($bn), 2010-2023
  • Figure 10: Dermatology Therapeutics Market, Global, Annual Revenue for Stelara ($bn), 2010-2023
  • Figure 11: Dermatology Therapeutics Market, Global, Annual Revenue for Neoral ($m), 2006-2023
  • Figure 12: Dermatology Therapeutics Market, Global, Annual Revenue for Protopic ($m), 2006-2015
  • Figure 13: Dermatology Therapeutics Market, Global, Revenue Forecast for Cosentyx ($bn), 2016-2023
  • Figure 14: Dermatology Therapeutics Market, Global, Revenue Forecast for Dupilumab ($bn), 2017-2023
  • Figure 15: Dermatology Therapeutics Market, Global, Revenue Forecast for Taltz ($bn), 2017-2023
  • Figure 16: Dermatology Therapeutics Market, Global, Revenue Forecast for Taltz ($bn), 2016-2023
  • Figure 17: Dermatology Therapeutics Market, Global, Revenue Forecast for Eucrisa ($bn), 2016-2023
  • Figure 18: Dermatology Therapeutics Market, Global, Revenue Forecast for AMG-827 ($m), 2016-2022
  • Figure 19: Dermatology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
  • Figure 20: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Stage of Development, Molecule Type and Program Type, 2017
  • Figure 21: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Stage of Development, 2017
  • Figure 22: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecule Type, 2017
  • Figure 23: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Molecular Target, 2017
  • Figure 24: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Molecular Target, 2017
  • Figure 25: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecular Target, 2017
  • Figure 26: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017
  • Figure 27: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
  • Figure 28: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
  • Figure 29: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
  • Figure 30: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
  • Figure 31: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017
  • Figure 32: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
  • Figure 33: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
  • Figure 34: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006-2016
  • Figure 35: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016
  • Figure 36: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
  • Figure 37: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
  • Figure 38: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006-2016
  • Figure 39: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
  • Figure 40: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016
  • Figure 41: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2017
  • Figure 42: Dermatology Therapeutics Market, Global, Revenue Forecast for Risankizumab ($m), 2016-2022
  • Figure 43: Dermatology Therapeutics Market, Global, Revenue Forecast for Zorblisa ($m), 2017-2023
  • Figure 44: Dermatology Therapeutics Market, Global, Revenue Forecast for Olumacostat glasaretil ($m), 2019-2023
  • Figure 45: Dermatology Therapeutics Market, Global, Revenue Forecast for Guselkumab ($m), 2016-2022
  • Figure 46: Dermatology Global, Market Size ($bn), 2016-2023
  • Figure 47: Dermatology Global, Annual Revenue Forecast for Key Products ($bn), 2016-2023
  • Figure 48: Dermatology, Global, Annual Revenue Forecast for Tumor Necrosis Factor-Alpha Inhibitors ($bn), 2016-2023
  • Figure 49: Dermatology, Global, Annual Revenue Forecast for Interleukin Inhibitors ($bn), 2015-2022
  • Figure 50: Dermatology, Global, Annual Revenue Forecast for Calcineurin Inhibitors ($bn), 2015-2022
  • Figure 51: Dermatology, Global, Annual Revenue Forecast for Glucocorticosteroids ($m), 2015-2022
  • Figure 52: Dermatology, Global, Annual Revenue Forecast for Phosphodiesterase 4 inhibitors ($bn), 2015-2023
  • Figure 53: Dermatology Therapeutics Market, Global, Cluster by Growth and Market Share, 2016-2023
  • Figure 54: Dermatology Therapeutics Market, Global, Forecast Market Share by Company (%), 2016-2023
  • Figure 55: Dermatology, Global, Companies by Compound Annual Growth Rate (%), 2016-2023
  • Figure 56: Dermatology, Global, Revenues by Product Type, 2016-2023
  • Figure 57: Dermatology, Global, Novartis, Annual Revenue Forecast ($bn), 2016-2023
  • Figure 58: Dermatology, Global, AbbVie Annual Revenue Forecast ($bn), 2016-2023
  • Figure 59: Dermatology, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2015-2022
  • Figure 60: Dermatology, Global, Sanofi, Annual Revenue Forecast ($bn), 2015-2022
  • Figure 61: Dermatology, Global, Pfizer Annual Revenue Forecast ($bn), 2015-2022
  • Figure 62: Dermatology, Global, Celgene Annual Revenue Forecast ($bn), 2016-2023
  • Figure 63: Dermatology, Global, Companies by Type, 2017
  • Figure 64: Dermatology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Dermatology Specialization, 2017
  • Figure 65: Dermatology, Global, Proportion of Total Company Revenue Attributed to Dermatology, 2015-2022
  • Figure 66: Dermatology, Global, Licensing Deals, 2006-2017
  • Figure 67: Dermatology, Global, Licensing Deals by Indication, 2006-2017
  • Figure 68: Dermatology, Global, Licensing Deals, 2006-2017
  • Figure 69: Dermatology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2017
  • Figure 70: Dermatology Therapeutics Market, Global, Licensing Deals, 2006-2017 (Part 1)
  • Figure 71: Dermatology Therapeutics Market, Global, Licensing Deals, 2006-2017 (Part 2)
  • Figure 72: Dermatology Therapeutics Market, Global, Licensing Deals, 2006-2017 (Part 3)
  • Figure 73: Dermatology Therapeutics Market, Global, Licensing Deals, 2006-2017 (Part 4)
  • Figure 74: Dermatology, Global, Co-development Deals, 2006-2017
  • Figure 75: Dermatology, Global, Co-development Deals by Indication, 2006-2017
  • Figure 76: Dermatology, Global, Co-development Deals, 2006-2017
  • Figure 77: Dermatology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2017
  • Figure 78: Dermatology Therapeutics Market, Global, Co-development Deals, 2006-2017 (Part 1)
  • Figure 79: Dermatology Therapeutics Market, Global, Co-development Deals, 2006-2017 (Part 2)
  • Figure 80: Dermatology Therapeutics Market, Global, Co-development Deals, 2006-2017 (Part 3)
  • Figure 81: Dermatology Therapeutics Market, Global, Co-development Deals, 2006-2017 (Part 4)
  • Figure 82: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 1
  • Figure 83: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 2
  • Figure 84: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 3
  • Figure 85: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 4
  • Figure 86: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 5
  • Figure 87: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 6
  • Figure 88: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 7
Back to Top